Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

CCO Oncology Podcast

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should have pharmacokinetic-guided therapy? Toxicities with PEGylated extended half-life products Factor VIII and bone health Factor VIII peaks, thrombotic risk, and cardiovascular disease Choosing between extended half-life products and emicizumab for active patients Role of fitusiran in the treatment paradigm if approved Presenters: Miguel A. Escobar, MD Professor of Medicine and Pediatrics Department of Hematology University of Texas Health Science Center McGovern Medical School Director Gulf States Hemophilia and Thrombophilia Center Houston, Texas Mark Reding, MD Professor of Medicine Division of Hematology, Oncology, and Transplantation Director Center for Bleeding and Clotting Disorders University of Minnesota Minneapolis, Minnesota Guy A. Young, MD Professor of Pediatrics Director, Hemostasis and Thrombosis Center Children’s Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles, California

Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G